Cincinnati Neuroscience Clinical Trials Research Center (CinciNEXT)

辛辛那提NEXT是独立的辛辛那提儿童医院医疗中心(CCHMC)和辛辛那提大学(UC)之间的独特合作，旨在继续成为NINDS资助的神经科学临床试验卓越网络(NeuroNEXT)网络中的一个临床网站。拟议申请的目的是确保所需的基础设施支持，以保持CincNEXT网站在第一个支持周期中为NeuroNEXT网络进行的杰出临床试验的质量。CincNEXT的具体目标包括简化启动、加强招聘、最大限度地保留和优化NeuroNEXT网络研究的研究进行。第二个目标是通过参与网络治理和网络委员会，为NeuroNEXT网络的全面成功作出积极贡献。第三个目标是实施对新的/初级临床研究人员的持续培训，以帮助他们发展参与和/或领导未来的NeuroNEXT和其他NINDS试验的技能和经验。这些目标将通过我们经验丰富的CincNEXT领导团队(两名联合PI和两名全职研究研究协调员)、热情的研究合作者、现有的优秀研究基础设施(包括CTSA)、可用于参与试验的患者的强大广度和深度以及两个支持性研究管理部门的共同努力来实现。两家机构都表明了他们对NeuroNEXT的承诺，同意继续使用标准化的主试验协议，采用IRB中央审查，并提供额外的机构资金来支持两名全职CincNEXT研究协调员(一名专注于儿科，一名专注于成人)。CincNEXT临床网站预计将继续为NeuroNEXT试验提供出色的招募、保留和数据质量，从而推动神经疾病的治疗。作为NeuroNEXT网络的一部分，CincNEXT网站是继续进行NINDS临床试验的理想地点。

CinciNEXT is a unique collaboration between the free standing Cincinnati Children's Hospital Medical Center (CCHMC) and the University of Cincinnati (UC) that aims to continue to be a clinical site in the NINDS-funded Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) network. The objective of the proposed application is to secure the infrastructural support needed to maintain the outstanding quality of clinical trials that the CinciNEXT site has conducted for the NeuroNEXT Network during the first cycle of support. Specific goals of CinciNEXT include to streamline startup, enhance recruitment, maximize retention and optimize study conduct of NeuroNEXT Network studies. A second goal is to actively contribute to the overall success of the NeuroNEXT network by participating in network governance and network committees. The third goal is to implement ongoing training of new/junior clinical investigators to help them develop skills and experience to participate and/or lead future NeuroNEXT and other NINDS trials. These goals will be achieved by the combination of our experienced CinciNEXT leadership team (two co-PIs and two fulltime research study coordinators), enthusiastic research collaborators, existing outstanding research infrastructure (including a CTSA), robust breadth and depth of patients available to participate in trials, and two supportive research administrations. Both institutions have shown their commitment to NeuroNEXT by agreeing to continue to use a standardized Master Trial Agreement, employ central IRB review, and provide additional institutional funds to support two full time CinciNEXT study coordinators (one pediatric focused and one adult focused). The CinciNEXT clinical site anticipates continuing to provide outstanding recruitment, retention and data quality for NeuroNEXT trials, and thereby advance treatments for neurological disorders. The CinciNEXT site is an ideal location to continue to conduct NINDS clinical trials as part of the NeuroNEXT network.